Heparin-modified dendrimer crosslinked collagen matrices for the delivery of heparin-binding epidermal growth factor

Journal of Biomedical Materials Research - Part A

Volumn 100 A, Issue 8, 2012, Pages 1929-1937

  Princz, M A ^a   Sheardown, H ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

collagen; corneal epithelium; dendrimers; heparin; heparin binding epidermal growth factor; tissue engineered corneal equivalents

Indexed keywords

COLLAGEN GELS; COLLAGEN MATRICES; CORNEAL EPITHELIUM; CROSSLINKED; DEVICE STABILITY; DOWN-REGULATION; EPIDERMAL GROWTH FACTORS; EXPOSURE-TIME; FIRST ORDER KINETICS; GROWTH FACTOR; HEPARIN; HEPARIN BINDING; HUMAN CORNEAL EPITHELIAL CELLS; IN-VITRO; LOW CONCENTRATIONS; SEEDING DENSITY;

BIOCHEMISTRY; CELL PROLIFERATION; COLLAGEN; DENDRIMERS; GELS; INTEGRATION; PEPTIDES; TISSUE;

POLYSACCHARIDES;

COLLAGEN GEL; DENDRIMER; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR;

ARTICLE; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA CELL; CORNEA EPITHELIUM; CORNEA TRANSPLANTATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN CROSS LINKING; PROTEIN STABILITY; RECEPTOR DOWN REGULATION; TISSUE ENGINEERED CORNEAL EQUIVALENT; TISSUE ENGINEERING;

ANIMALS; CATTLE; CELL PROLIFERATION; COLLAGEN; CORNEA; CROSS-LINKING REAGENTS; DENDRIMERS; EPITHELIAL CELLS; GELS; HEPARIN; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; IODINE RADIOISOTOPES; SUS SCROFA;

EID: 84862755415     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34128     Document Type: Article

References (63)

1. Duan X, Klenkler BJ, Sheardown H,. Progress in the development of a corneal replacement: Keratoprostheses and tissue-engineered corneas. Expert Rev Med Devices 2006; 3: 59-72.
2. Chirila TV, Hicks CR, Dalton PD, Vijayasekaran S, Lou X, Hong Y, Clayton AB, Ziegelaar BW, Fitton JH, Platten S, Crawford GJ, Constable IJ,. Artificial Cornea. Prog Polym Sci 1998; 23: 447-473.
3. George A, Pitt WG,. Comparison of corneal epithelial cellular growth on synthetic cornea materials. Biomaterials 2002; 23: 1369-1373.
4. Griffith M, Li F, Lohman C, Sheardown H, Shimmura S, Carlsson DJ,. Tissue engineering of the cornea. Scaffolds Tissue Eng Ma P and Ellisieff J (eds) CRC Press. 2005: 403-413.
5. Zieske JD,. Extracellular matrix and wound healing. Curr Opin Ophthalmol 2001; 12: 237-241.
6. Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S,. Growth factors: Importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res 2000; 19: 113-129.
7. Reid TW,. Growth control of cornea and lens epithelial cells. Prog Retin Eye Res 1994; 13: 507-554.
8. Sheardown H, Clark H, Wedge C, Apel R, Rootman D, Cheng YL,. A semi-solid drug delivery system for epidermal growth factor in corneal epithelial wound healing. Curr Eye Res 1997; 16: 183-190.
9. Schultz CL, Morck DW,. Contact lenses as a drug delivery device for epidermal growth factor in the treatment of ocular wounds. Clin Exp Optom 2010; 93: 61-65.
10. Hori K, Sotozono C, Hamuro J, et al. Controlled-release of epidermal growth factor from cationized gelatin hydrogel enhances corneal epithelial wound healing. J Control Release 2007; 118: 169-176.
11. Klenkler BJ, Griffith M, Becerril C, West-Mays JA, Sheardown H,. EGF-grafted PDMS surfaces in artificial cornea applications. Biomaterials 2005; 26: 7286-7296.
12. Klenkler BJ, Sheardown H,. Characterization of EGF coupling to aminated silicone rubber surfaces. Biotechnol Bioeng 2006; 95: 1158-1166.
13. Klenkler BJ, Dwivedi D, West-Mays JA, Sheardown H,. Corneal epithelial cell adhesion and growth on EGF-modified aminated PDMS. J Biomed Mater Res A 2010; 93: 1043-1049.
14. Yu FS, Yin J, Xu K, Huang J,. Growth factors and corneal epithelial wound healing. Brain Res Bull 2010; 81: 229-235.
15. Nishi E, Klagsbrun M,. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a mediator of multiple physiological and pathological pathways. Growth Factors 2004; 22: 253-260.
16. Thompson SA, Higashiyaman S, Wood K, Pollitt NS, Damm D, McEnroe G, Garrick B, Ashton N, Lau K, Hancock N, Klagsburn M, Abraham JA,. Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. J Biol Chem 1993; 269: 2541-2549.
17. Iwamoto R, Mekada E,. Heparin-binding EGF-like growth factor: A juxtacrine growth factor. Cytokine Growth Factor Rev 2000; 11: 335-344.
18. Wilson SE, He YG, Weng J, Zieske JD, Jester JV, Schultz GS,. Effect of epidermal growth factor, hepatocyte growth factor, and keratinocyte growth factor, on proliferation, motility and differentiation of human corneal epithelial cells. Exp Eye Res 1994; 59: 665-678.
19. Yoshioka R, Shiraishi A, Kobayashi T, Morita S, Hayashi Y, Higashiyama S, Ohashi Y,. Corneal epithelial wound healing impaired in keratinocyte-specific HB-EGF-deficient mice in vivo and in vitro. Invest Ophthalmol Vis Sci 2011; 51: 5630-5639.
20. Xu KP, Ding Y, Ling J, Dong Z, Yu FX,. Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells. Invest Ophthalmol Vis Sci 2004; 45: 813-820.
21. Joung YK, Bae JW, Park KD,. Controlled release of heparin-binding growth factors using heparin-containing particulate systems for tissue regeneration. Expert Opin Drug Deliv 2008; 5: 1173-1184.
22. Zhang S, Uladag H,. Nanoparticulate systems for growth factor delivery. Pharm Res 2009; 26: 1561-1580.
23. Rai B, Nurcombe V, Cool SM,. Heparan sulfate-based treatments for regenerative medicine. Crit Rev Eukaryot Gene Expr 2011; 21: 1-12.
24. Meek KM, Boote C,. The organization of collagen in the corneal stroma. Exp Eye Res 2004; 78: 503-512.
25. Germain L, Auger FA, Grandbois E, Guignard R, Giasson M, Boisjoly H, Guérin SL,. Reconstructed human cornea produced in vitro by tissue engineering. Pathobiology 1999; 67: 140-147.
26. Orwin EJ, Borene ML, Hubel AJ,. Biomechanical and optical characteristics of a corneal stromal equivalent. Biomech Eng 2003; 125: 439-444.
27. Xu YG, Xu YS, Huang C, Feng Y, Li Y, Wang W,. Development of a rabbit corneal equivalent using an acellular corneal matrix of a porcine substrate. Mol Vis 2008; 14: 2180-2189.
28. Bentley E, Murphy CJ, Li F, Carlsson DJ, Griffith M,. Biosynthetic corneal substitute implantation in dogs. Cornea 2010; 29: 910-916.
29. Duan X, Sheardown H,. Crosslinking of collagen with dendrimers. J Biomed Mater Res A 2005; 75: 510-518.
30. Princz MA, Sheardown H,. Modified dendrimer crosslinked collagen matrices. J Biomat Sci Polymer Ed. Forthcoming.
31. Duan X, Sheardown H,. Dendrimer crosslinked collagen as a corneal tissue engineering scaffold: Mechanical properties and corneal epithelial cell interactions. Biomaterials 2006; 27: 4608-4617.
32. Duan X, McLaughlin C, Griffith M, Sheardown H,. Biofunctionalization of collagen for improved biological response: scaffolds for corneal tissue engineering. Biomaterials 2007; 28: 78-88.
33. Duan X, Sheardown H,. Incorporation of cell-adhesion peptides into collagen scaffolds promotes corneal epithelial stratification. J Biomater Sci Polymer Ed 2007; 18: 701-711.
34. Princz MA, Sheardown H,. Heparin-modified dendrimer cross-linked collagen matrices for the delivery of basic fibroblast growth factor (FGF-2). J Biomater Sci Polym Ed 2008; 19: 1201-1218.
35. Gingras ME, Larouche K, Larouche N, Leclerc S, Salesse C, Guérin SL,. Regulation of the integrin subunit alpha5 gene promoter by the transcription factors Sp1/Sp3 is influenced by the cell density in rabbit corneal epithelial cells. Invest Ophthalmol Vis Sci 2003; 44: 3742-3755.
36. Wilson SE, Netto M, Ambrosio R Jr,. Corneal cells: Chatty in development, homeostasis, wound healing and disease. Am J Ophthalmol 2003; 136: 530-536.
37. Griffith M, Hakim M, Shimmura S, Watsky MA, Li F, Carlsson D, Doillon CJ, Nakamura N, Suuronen E, Shinozaki N, Nakata K, Sheardown H,. Artificial human corneas: Scaffolds for transplantation and host regeneration. Cornea 2002; 21: S54-S61.
38. Harvima IT, Lappalainen K, Hirvonen MR, Matto M, Kivinen PK, Hyttinen M, Pelkonnen J, Naukkarinen A,. Heparin modulates the growth and adherence and augments the growth-inhibitory action of TNF-α on cultured human keratinocytes. J Cell Biochem 2004; 92: 372-386.
39. Denk PO, Knorr M,. Effect of heparin on human corneal fibroblast proliferation in vitro with and without growth factor stimulation. Graefe's Arch Clin Exp Ophthalmol 1999; 237: 342-347.
40. Leonardi A, Papa V, Fregona I, Russo P, De Franchis G, Milazzo G,. In vitro effects of fluoroquinolone and aminoglycoside antibiotics on human keratocytes. Cornea 2006; 25: 85-90.
41. Ono A, Kanno H, Hayashi A, Nishimura S, Kyuma Y, Sato H, Ito S, Shimizu N, Chang CC, Gondo G, Yamamoto I, Sasaki T, Tanaka M,. Collagen gel matrix assay as an in vitro chemosensitivity test for malignant astrocytic tumors. Int J Clin Oncol 2007; 12: 125-130.
42. Zhou Y, Besner GE,. Heparin-binding epidermal growth factor-like growth factor is a potent neurotrophic factor for PC12 cells. Neurosignals 2010; 18: 141-151.
43. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M,. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251: 936-939.
44. Nakamura M, Nishida T,. Differential effects of epidermal growth factor and interleukin 6 on corneal epithelial cells and vascular endothelial cells. Cornea 1999; 18: 452-458.
45. Forsten-Williams K, Chu CL, Fannon M, Buczek-Thomas JA, Nugent MA,. Control of growth factor networks by heparan sulfate proteoglycans. Ann Biomed Eng 2008; 36: 2134-2148.
46. Prince RN, Schreiter ER, Zou P, Wiley HS, Ting AY, Lee RT, Lauffenburger DA,. The heparin-binding domain of HB-EGF mediates localization to sites of cell-cell contact and prevents HB-EGF proteolytic release. J Cell Sci 2010; 123: 2308-2318.
47. Nakamura K, Iwamoto R, Mekada E,. Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form a complex with integrin alpha 3 beta 1 at cell-cell contact sites. J Cell Biol 1995; 129: 1691-1705.
48. Kanematsu A, Yamamoto S, Ozeki M, Noguchi T, Kanatani I, Ogawa O, Tabata Y,. Collagenous matrices as release carriers of exogenous growth factors. Biomaterials 2004; 25: 4513-4520.
49. Kanematsu A, Marui A, Yamamoto S, Ozeki M, Hirano Y, Yamamoto M, Ogawa O, Komeda M, Tabata Y,. Type I collagen can function as a reservoir of basic fibroblast growth factor. J Control Rel 2004; 99: 281-292.
50. Saltzman WM,. Controlled Drug Delivery Systems. Drug Delivery: Engineering Principles for Drug Therapy. Oxford University Press, New York, NY; 2001. p 235-280.
51. Chu CL, Goerges AL, Nugent MA,. Identification of common and specific growth factor binding sites in heparan sulfate proteoglycans. Biochemistry 2005; 44: 12203-12213.
52. Gospodarowicz D, Cheng J,. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986; 128: 475-484.
53. Schroeder-Tefft JA, Bentz H, Estridge TD,. Collagen and heparin matrices for group factor delivery. J Control Rel 1997; 49: 291-298.
54. Wissink MJB, Beernink R, Poot AA, Engbers GHM, Beugeling T, van Aken WG, Feijen J,. Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J Control Rel 2000; 64: 103-114.
55. van Wachem PB, Plantinga JA, Wissink MJB, Beernink R, Poot AA, Engbers GHM, Beugeling T, van Aken WG, Feigen J, van Luyn MJA,. In vivo biocompatibility of carbodiimide-crosslinked collagen matrices: Effects of crosslink density, heparin immobilization and bGFG loading. J Biomed Mater Res 2001; 55: 368-378.
56. Pieper JS, Hafmans T, van Wachem PB, van Luyn MJ, Brouwer LA, Veerkamp JH, van Kuppevelt TH,. Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. J Biomed Mater Res 2002; 62: 185-194.
57. Steffens GC, Yao C, Prevel P, Markowicz M, Schenck P, Noah EM, Pallua N,. Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng 2004; 10: 1502-1509.
58. Yao C, Roderfeld M, Rath T, Roeb E, Bernhagen J, Steffens G,. The impact of proteinase-induced matrix degradation on the release of VEGF from heparinized collagen matrices. Biomaterials 2006; 27: 1608-1616.
59. Sun B, Chen B, Zhao Y, Sun W, Chen K, Zhang J, Wei Z, Xiao Z, Dai J,. Crosslinking heparin to collagen scaffolds for the delivery of human platelet-derived growth factor. J Biomed Mater Res B 2009; 91: 366-372.
60. Bladergroen BA, Siebum B, Siebers-Vermeulen KG, van Kuppevelt TH, Poot AA, Feijen J, Figdor CG, Torensma R,. In vivo recruitment of hematopoietic cells using stromal cell-derived factor 1 alpha-loaded heparinized three-dimensional collagen scaffolds. Tissue Eng A 2009; 15: 1591-1599.
61. Nillesen STM, Geutjes PJ, Wismans R, Schalkwijk J, Daamen WF, van Kuppevelt TH,. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF-2 and VEGF. Biomaterials 2007; 28: 1123-1131.
62. Wolf-Brandstetter C, Lode A, Hanke T, Scharnweber D, Worch H,. Influence of modified extracellular matrices on Ti6AL4V implants on binding and release of VEGF. J Biomed Mater Res A 2006; 79: 882-894.
63. Teixeira S, Yang L, Dijkstra PJ, Ferraz MP, Monteiro FJ,. Heparinized hydroxyapatite/collagen three-dimensional scaffolds for tissue engineering. J Biomed Mater Res 2010; 21: 2385-2392.